Known hypersensitivity to -fluorouracil/leucovorin
Known hypersensitivity to irinotecan
Patients must not have any known previous or concurrent condition suggesting susceptibility to hypersensitivity or allergic reactions, including, but not limited to: known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies; patients with mild or seasonal allergies may be included after discussion with the study chairs
Patients with known hypersensitivity to any TZD oral agents are not eligible
Known hypersensitivity to any oligodeoxynucleotide.
Hypersensitivity to carboplatin or cisplatin
Hypersensitivity to taxanes (such as Steven Johnson syndrome). Hypersensitivity, such as rash < Grade  that is managed, is allowed.
Patients with a known hypersensitivity to carboplatin
Hypersensitivity to:
Subjects with a hypersensitivity to sirolimus.
Known hypersensitivity to one or more of the study agents used
Known hypersensitivity to platinum compounds
History of known hypersensitivity to cetuximab, docetaxel or similar agents
Known hypersensitivity to the metal in the electrodes (stainless steel  L) that cannot be medically managed
Known hypersensitivity to methotrexate
No known hypersensitivity to trastuzumab
Patients with a known hypersensitivity to treosulfan and/or fludarabine
Previously known hypersensitivity to any of the agents used in this study; known sensitivity to melphalan
The patient has known hypersensitivity to gelatin or lactose monohydrate
Known hypersensitivity to the device constituent or TARIS Inserter materials.
Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product
Known hypersensitivity to cetuximab or other EGFR antibody
Has known hypersensitivity to baker's yeast
Previously known hypersensitivity to any of the agents used in this study; known sensitivity to busulfan or fludarabine
Documented hypersensitivity to bumetanide or sulfonamides
Has hypersensitivity to nivolumab or any other drug used in this protocol
Known hypersensitivity to one or more of the study agents
Known hypersensitivity to any of the study agents used
Known hypersensitivity to study drug and/or drug class
Has a known hypersensitivity to any of the study therapy products
Known hypersensitivity to any study drug used in this trial
Known hypersensitivity to deferasirox
Known hypersensitivity to any study drug
Known hypersensitivity to either study drug (umbralisib or ibrutinib)
Known hypersensitivity to S- or its metabolites (eg, -FU);
Known hypersensitivity to one or more of the study agents
Previously known hypersensitivity to any of the agents used in this study
Previously known hypersensitivity to any of the agents used in this study
Hypersensitivity to simvastatin or ezetimibe.
Patients with known hypersensitivity to taxanes or platinums are to be excluded
Known or possible hypersensitivity to palbociclib (CTCAE version [V] .)
Subject has a known hypersensitivity to pembrolizumab or any of its ingredients
Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to fluorouracil
Patients with a known hypersensitivity to interferon-alpha
Known hypersensitivity to -FU injection, poor nutritional state, known dipyrimidine dehydrogenase deficiency, or taking sorivudine (such as Usevir, Bravavir, etc.)
Patients with known hypersensitivity to pegfilgrastim and filgrastim
Known hypersensitivity to one or more of the study agents
Hypersensitivity of TZD
Known or suspected hypersensitivity to ruxolitinib.
Previously known hypersensitivity to any of the agents used in this study
Prior use of gossypol or AT-, or known hypersensitivity to gossypol or AT-
Hypersensitivity to mithramycin
Patients with a known hypersensitivity to any of the study agents
Hypersensitivity to fluphenazine or other phenothiazines
Hypersensitivity to any reagents used in the study.
Known hypersensitivity to any study drug
Known hypersensitivity to enzalutamide
Known hypersensitivity to any of the study agents
Hypersensitivity to acetazolamide or sulfonamides
Known hypersensitivity to arsenic trioxide
Known hypersensitivity to Cremophor-based agents
patient has known hypersensitivity to alpelisib, fulvestrant or letrozole
No known hypersensitivity to Escherichia (E.) coli-derived products
TREATMENT: Patients with known hypersensitivity reaction to dacarbazine are ineligible to receive temozolomide
Hypersensitivity to mithramycin
Known hypersensitivity to cetuximab or other EGFR antibody
Known hypersensitivity to inactive ingredient of bevacizumab
Known hypersensitivity to inactive ingredient of TPI 
Known hypersensitivity to any of the study agents used
Hypersensitivity to any of the study medications
Patients with known hypersensitivity to temozolomide or dacarbazine are not eligible
With known hypersensitivity to treosulfan or fludarabine (fludarabine phosphate)
Patients who have hypersensitivity to sitagliptin
Documented hypersensitivity to clobetasol
Must not have known hypersensitivity to -aminoquinoline compound
Patients with a known hypersensitivity to BKM, RAD (including other rapalogs) or their excipient
Hypersensitivity to interferon alfa
Suspected hypersensitivity to IFN alfab
Patients with known Aspirin-Hypersensitivity triad (asthma, allergic rhinitis, ASA hypersensitivity).
Patients with known hypersensitivity to celecoxib or other NSAIDs, aspirin or sulfonamides.
Known history of immunogenicity or hypersensitivity to a CD antibody.
Known hypersensitivity to any component of the investigational products; known hypersensitivity to salicylates; known hypersensitivity to aspartame-containing products for patients with phenylketonuria; known allergies to any of the medications or components of medications used in the trial
Patients must not have known hypersensitivity to irinotecan, fluorouracil, or leucovorin
Hypersensitivity or prior treatment with obinutuzumab
Known hypersensitivity to the study treatment or any of its ingredients.
Known history of immunogenicity or hypersensitivity to a CD antibody.
Known hypersensitivity to -fluorouracil/leucovorin
Known hypersensitivity to irinotecan
Prior treatment with or hypersensitivity to study drug or related compounds
Known hypersensitivity to bicalutamide.
Patients with known hypersensitivity to any TZD oral agents are not eligible
Previously known hypersensitivity to any of the agents used in this study
Known hypersensitivity to one or more of the study agents
Known hypersensitivity to any study drug
Previously known hypersensitivity to any of the agents used in this study
Patients with known hypersensitivity to any oligodeoxynucleotide.
Known hypersensitivity to enzalutamide or related compounds
Known hypersensitivity to acyclovir or similar anti-viral drug
Has a known hypersensitivity to any of the study therapy products
Known hypersensitivity to ibrutinib
Subject has a known hypersensitivity to platinum compounds.
Known hypersensitivity to everolimus or bendamustine
Known hypersensitivity to trial drug
Subject has a known hypersensitivity to platinum compounds.
Known hypersensitivity to -fluorouracil/leucovorin
Known hypersensitivity to capecitabine
Known hypersensitivity to irinotecan
Known hypersensitivity to acyclovir or similar anti-viral drug
Known hypersensitivity to pembrolizumab or another mAb.
Known hypersensitivity to both allopurinol and rasburicase
Known hypersensitivity reaction to mushroom products
Patients with a known hypersensitivity to tacrolimus
Known anaphylactic or severe hypersensitivity to dasatinib or crizotinib or their analogs
No known hypersensitivity to -aminoquinoline compound
Patients with hypersensitivity to any tetracyclines
No known hypersensitivity to ofatumumab, humanized antibodies or chemotherapy agents throughout the protocol
The patient has known hypersensitivity to bovine proteins
Hypersensitivity to acyclovir or similar anti-viral drug
Known hypersensitivity to cetuximab or other EGFR antibody
Known hypersensitivity to any of the study agents used
Known hypersensitivity to any of the study agents
Known hypersensitivity to any of the following: diphtheria toxoid, neomycin, polymyxin B, streptomycin,  phenoxyethanol, formaldehyde, aluminum hydroxide, yeast
Known hypersensitivity to fluoropyrimidines or cisplatin.
Patients with known hypersensitivity to any oligodeoxynucleotide that cannot be adequately managed with appropriate prophylaxis; e.g. steroids.
Prior treatment with or have known hypersensitivity to AL.
b. Indication B- LMS: Prior treatment with or have known hypersensitivity to dacarbazine.
c. Indication C - SS: Prior treatment with or have known hypersensitivity to dacarbazine.
Has known hypersensitivity to baker's yeast
Known hypersensitivity to sirolimus.
History of Grade ?  infusion-associated AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine or acetaminophen
Subject has known history of serious hypersensitivity reaction to a known ingredient of ASP, erlotinib or gefitinib.
Known history of ? Grade  hypersensitivity to a therapeutic antibody.
Known hypersensitivity to any constituent of the study medication.
Known hypersensitivity to -azacytidine\r\n* Prior treatment with -azacytidine is allowed
Known hypersensitivity to dacarbazine (DTIC).
Known hypersensitivity to any inactive ingredient of bevacizumab
Known hypersensitivity to any inactive ingredient of TPI 
Known hypersensitivity to lithium or tretinoin
Has a known hypersensitivity to baker's yeast or has an active yeast infection;
Patients with hypersensitivity to amiodarone or NAC
Hypersensitivity to obinutuzumab
Subjects with porphyrias or known hypersensitivity to porphyrins
No known hypersensitivity to trastuzumab or pertuzumab
Known hypersensitivity to rosuvastatin
Patients in the combination arms - known hypersensitivity to fulvestrant
Known hypersensitivity to filgrastim, plerixafor, or Escherichia (E.) coli derived products
Known hypersensitivity to any of the treatment ingredients. Known previous Grade - infusion related reactions with anti-EGFR mABs
Have known hypersensitivity to platinum (Pt) compounds
Hypersensitivity to recombinant human IL-
Known hypersensitivity to Tween-, or human immunoglobulin
Known hypersensitivity to study-assigned chemotherapy
Known hypersensitivity to any study drug
Known hypersensitivity to NSAIDs
Known hypersensitivity to varenicline
Suspected hypersensitivity to interferon alpha
Known hypersensitivity to polymyxin B
Hypersensitivity to trial medications
Known hypersensitivity to other Src/Abl non-receptor kinase inhibitors.
Known hypersensitivity to ibrutinib or nivolumab
Known hypersensitivity to sirolimus
Known hypersensitivity to human albumin
Have known hypersensitivity to pancuronium bromide, atracurium or cisatracurium,
Have known hypersensitivity to ciprofloxacin or any member of the quinolone class of antimicrobial agents,
Have a known hypersensitivity to olanzapine or to phenothiazines
Patients known to have hypersensitivity to dacarbazine (DTIC) are not eligible
Known hypersensitivity to cold
Hypersensitivity to pregabalin
Hypersensitivity to ginseng
Patients with known hypersensitivity to octreotide or somatostatin
Known or suspected hypersensitivity to any of the constituents of the investigational product
Patients with hypersensitivity to any tetracycline
Any known hypersensitivity to dexmedetomidine
Patients with hypersensitivity to tetracyclines
Minocycline trial only: patients with hypersensitivity to any tetracyclines
Patients with known hypersensitivity to sildenafil or other ingredients of sildenafil
History of known latex hypersensitivity
Known hypersensitivity or history of hypersensitivity to dimethylsulfoxide (DMSO)
History of known latex hypersensitivity
Known hypersensitivity to NAC
Patients who have hypersensitivity to sitagliptin
Known hypersensitivity to cyclophosphamide or any of its metabolites
Known hypersensitivity to one or more of the study agents
Has suspected or known hypersensitivity to ingredients of MK- (letermovir) formulations
Subjects with a known hypersensitivity to calcitriol
The patient has a known hypersensitivity to Lymphazurin or Lymphoseek
Known hypersensitivity to polyethylene glycol (PEG) 
Known hypersensitivity to trastuzumab or pertuzumab
Hypersensitivity or anaphylactic reaction to any somatostatin analog or to maytansinoids
The subject has a known hypersensitivity to Isosulfan Blue Dye.
Known hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug
EXCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: Known hypersensitivity to zolpidem or chemically related compounds; history of serious adverse reactions or hypersensitivity to any drug
Known hypersensitivity to NSAIDs
Patients with known hypersensitivity including anaphylaxis to trabectedin
Known hypersensitivity to NSAIDs
Hypersensitivity to Caphosol ingredients
Known hypersensitivity to tartrazine, a dye used in the ensartinib  mg capsule.
Known history of immunogenicity or hypersensitivity to a CD antibody.
